• Corpus ID: 44217914

Clinicopathological factors associated to HER-2 status in a hospital-based sample of breast cancer patients in Puerto Rico.

  title={Clinicopathological factors associated to HER-2 status in a hospital-based sample of breast cancer patients in Puerto Rico.},
  author={Ana P Ortiz and Orqu{\'i}dea Fr{\'i}as and Carmen I Gonz{\'a}lez-Keelan and Erick L. Su{\'a}rez and David Cap{\'o} and Javier P{\'e}rez and Fernando Guiberteau Cabanillas and Edna M. Mora},
  journal={Puerto Rico health sciences journal},
  volume={29 3},
Breast cancer is the most common female malignancy in Puerto Rico. Cases with human epidermal growth factor receptor 2 (HER-2) oncoprotein overamplification are associated with aggressive clinical behavior. Given the limited availability of information for Puerto Rico, we aimed to evaluate the prevalence and clinical correlates of HER-2 gene overexpression among a hospital-based female population of breast cancer cases. We analyzed data from 1,049 female patients with invasive breast cancer… 
3 Citations
Breast cancer molecular subtypes and survival in a hospital-based sample in Puerto Rico
This is the most comprehensive epidemiological study to date on the impact of hormone receptor expression subtypes in BC survival in Puerto Rico and consistent to results in other populations, the TN subtype and HER‐2+ tumors were associated with decreased survival.
Application of FISH Technique in Evaluation of Equivocal Cases of HER2/neu in Breast Carcinoma
In this study, HER2/neu was statistically inversely associated with both ER and PR receptors and is in inverse statistically significant correlation with estrogen and progesterone receptors while not statistically significant with age and histological types of tumors.
Prevalence of breast and ovarian cancer subtypes in Hispanic populations from Puerto Rico
The data suggests that OC and BC subtypes distribution in Hispanic populations from PR are in-line with national averages and provides an opportunity to further study this population separate from other US Hispanic populations.


Her-2/neu gene overexpression in breast carcinoma and its association with clinicopathological characteristics of the disease.
The pathological and clinical characteristics of Her-2/neu positive and negative subsets differ, and Her- 2/neU overexpression was associated with other poor prognostic factors of age, tumour size and number of nodes involved.
Patterns of HER2 testing in the management of primary breast cancer.
Variation in which breast cancer patients received HER2 testing appears to reflect expectations about a woman's prognosis, as current guidelines call for all tumors to be assessed in order to adequately characterize prognosis and determine eligibility for HER2-targeted therapy.
Her-2/neu oncogene expression in Puerto Rican females with breast cancer.
The incidence of Her2 overexpression found in this database was somewhat lower than the one reported in the literature, this might also be due to the small cohort examined or to the technique utilized.
The association of HER-2/neu amplification with breast cancer recurrence.
The HER-2/neu oncogene is an independent prognostic indicator of a subset of breast cancers that are at high risk of early recurrence, regardless of tumor grade, estrogen/progesterone receptor status, and lymph node status.
Prevalence of steroid receptors and HER 2/neu in breast cancer biopsies of women living in Puerto Rico.
There is a lower prevalence of estrogen receptor in the breast cancer biopsies of women living in Puerto Rico than their USA counterparts, but similar prevalence of progesterone receptor status and HER 2/neu protein over expression.
Differences in breast cancer risk factors by tumor marker subtypes among premenopausal Vietnamese and Chinese women.
  • H. Nichols, A. Trentham-Dietz, +5 authors P. Newcomb
  • Medicine
    Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • 2005
The hypothesis that some breast cancer risk factors differ by ER and HER-2/neu tumor marker subtypes is supported, as well as an inverse trend between increasing parity and decreasing breastcancer risk.
Association between tumour characteristics and HER-2/neu by immunohistochemistry in 1362 women with primary operable breast cancer
ER, PR, and tumour grade are independent predictors for HER-2/neu overexpression in women with primary operable breast cancer, and in Women with ER+ tumours, PR status also affects the likelihood of Her-2-neu expression.
The Association Of Her-2/Neu Overexpression In Relation With P53 Nuclear Accumulation, Hormonal Recceptor Status And Common Clinicopathological Prognostic Parameters In A Series Of Egyptian Women With Inasive Ductal Carcinoma
Her-2/neu may be a powerful predictor of poor prognosis as it’s over-expression was strongly directly correlated with p53 nuclear accumulation, tumor size and grade and inversely correlated with hormonal receptor status of breast carcinoma.
High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller.
Patients with HER2-positive T1abN0M0 tumors have a significant risk of relapse and should be considered for systemic, anti-HER2, adjuvant therapy.
Follow-up study of HER-2/neu amplification in primary breast cancer.
While HER-2/neu amplification may be biologically important in primary breast cancer, it will only be of marginal utility as a prognostic factor for predicting clinical outcome.